Literature DB >> 20818736

Emerging therapeutic approaches to mitochondrial diseases.

Tina Wenz1, Sion L Williams, Sandra R Bacman, Carlos T Moraes.   

Abstract

Mitochondrial diseases are very heterogeneous and can affect different tissues and organs. Moreover, they can be caused by genetic defects in either nuclear or mitochondrial DNA as well as by environmental factors. All of these factors have made the development of therapies difficult. In this review article, we will discuss emerging approaches to the therapy of mitochondrial disorders, some of which are targeted to specific conditions whereas others may be applicable to a more diverse group of patients. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818736     DOI: 10.1002/ddrr.109

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  15 in total

Review 1.  Mitochondrial disorders caused by mutations in respiratory chain assembly factors.

Authors:  Francisca Diaz; Heike Kotarsky; Vineta Fellman; Carlos T Moraes
Journal:  Semin Fetal Neonatal Med       Date:  2011-06-15       Impact factor: 3.926

Review 2.  Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases.

Authors:  Martine Uittenbogaard; Anne Chiaramello
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Mitochondrial disorders and the eye.

Authors:  Nicole J Van Bergen; Rahul Chakrabarti; Evelyn C O'Neill; Jonathan G Crowston; Ian A Trounce
Journal:  Eye Brain       Date:  2011-09-26

Review 4.  Bioenergetic medicine.

Authors:  Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 5.  Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.

Authors:  Lefkothea C Papadopoulou; Asterios S Tsiftsoglou
Journal:  Pharm Res       Date:  2011-08-27       Impact factor: 4.200

6.  The use of mitochondria-targeted endonucleases to manipulate mtDNA.

Authors:  Sandra R Bacman; Sion L Williams; Milena Pinto; Carlos T Moraes
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

Review 7.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

8.  A defect in the mitochondrial complex III, but not complex IV, triggers early ROS-dependent damage in defined brain regions.

Authors:  Francisca Diaz; Sofia Garcia; Kyle R Padgett; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2012-08-21       Impact factor: 6.150

9.  Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.

Authors:  Mohammad A Esmaeili; Shilpi Yadav; Ravi Kr Gupta; Garrett R Waggoner; Abigail Deloach; Noel Y Calingasan; M Flint Beal; Mahmoud Kiaei
Journal:  Hum Mol Genet       Date:  2015-11-24       Impact factor: 6.150

10.  Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease.

Authors:  S R Bacman; S L Williams; D Duan; C T Moraes
Journal:  Gene Ther       Date:  2011-12-01       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.